Crinetics Pharmaceuticals ( (CRNX) ) just unveiled an announcement.
On February 24, 2025, Crinetics Pharmaceuticals announced the appointment of Tobin Schilke as Chief Financial Officer, effective February 28, 2025. Mr. Schilke brings over 25 years of global pharmaceutical experience, having previously transformed biotech companies into commercial organizations. His appointment is seen as pivotal as Crinetics prepares for its first commercial launch and advances its development pipeline. The move is expected to accelerate Crinetics’ growth objectives and create long-term value for stakeholders.
More about Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Its lead development candidate, paltusotine, is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors, while atumelnant is being developed for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome.
YTD Price Performance: -27.33%
Average Trading Volume: 838,078
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $3.47B
For detailed information about CRNX stock, go to TipRanks’ Stock Analysis page.